AHCO vs INMD โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AHCO Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to AdaptHealth Corp. Common Stock (AHCO) driven by superior Valuation, Momentum & Technical, Options & Structure while INMD counters with relative strength in Growth & Margin. Fundamentally, AHCO trades at 7.8x Forward P/E with 3.8% operating margin (+10.9% YoY revenue) versus INMD at 9.2x Forward P/E and 17.9% operating margin (-1.1% YoY). In options structure, AHCO sits in SURGE (12th %ile IV; Dealer Gamma Walls on Pro) against INMD sits in CONSOLIDATION (12th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | AHCO Revenue | INMD Revenue | AHCO Op. Margin | INMD Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $350M | $100M | 9.0% | 23.5% | INMD |
| FY2019 | $530M | $160M | 5.5% | 38.1% | INMD |
| FY2020 | $1.06B | $210M | 6.8% | 35.3% | INMD |
| FY2021 | $2.45B | $360M | 9.2% | 46.8% | INMD |
| FY2022 | $2.97B | $450M | 6.4% | 43.6% | INMD |
| FY2023 | $3.20B | $490M | -18.7% | 39.8% | INMD |
| FY2024 | $3.26B | $390M | 8.1% | 28.5% | INMD |
| FY2025 | $3.24B | $370M | 2.8% | 23.0% | INMD |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AHCO | INMD | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $989.8M | $730.8M | Larger Scale | AHCO |
| Trailing P/E Ratio Valuation | 7.8x | 10.8x | Lower Multiple | AHCO |
| Forward P/E Ratio Valuation | 7.8x | 9.2x | Lower Multiple | AHCO |
| Revenue Growth (YoY) Growth | +10.9% | -1.1% | Higher Growth | AHCO |
| Operating Margin (TTM) Profitability | 3.8% | 17.9% | Higher Margin | INMD |
| Net Profit Margin Profitability | -11.8% | 20.0% | Higher Margin | INMD |
| Return on Equity (ROE) Capital Efficiency | -28.4% | 11.4% | Higher ROE | INMD |
| 52-Week Range Position Momentum | 24% ($5โ$13) | 0% ($12โ$17) | Stronger Trend | AHCO |
| Beta / 30D Volatility Risk Regime | 0.17ฮฒ ยท 67% Vol | 0.61ฮฒ ยท 35% Vol | Lower Realized Risk | INMD |
| Unified Institutional Score Composite Signal | 45.2 / 100 (HOLD) | 37.6 / 100 (SELL) | Higher Composite | AHCO |